Established by Prof. Raymond Kaempfer and Dr. Gila Arad from the faculty of medicine at the Hebrew University, Atox Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients.
Reltecimod, Atox Bio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life threatening infection for which no therapy currently exists.
Atox Bio r...
Established by Prof. Raymond Kaempfer and Dr. Gila Arad from the faculty of medicine at the Hebrew University, Atox Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients.
Reltecimod, Atox Bio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life threatening infection for which no therapy currently exists.
Atox Bio recently completed enrollment of the ACCUTE (Reltecimod Clinical Composite endpoint Study in necrotizing soft Tissue InfEctions) study, a phase 3 clinical trial evaluating the efficacy of Reltecimod in patients with NSTI.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.